Liquidia settles all litigation with United Therapeutics, paying $380.7 million and keeping YUTREPIA on the market
+3 new sources since this summary was written
Liquidia Corporation and United Therapeutics reached a global settlement that resolves six pending lawsuits, including patent, trade‑secret and antitrust claims. Liquidia will make net payments of $380.7 million in installments through 2027, with an initial $175 million due within 30 days. The agreement leaves YUTREPIA inhalation powder available for pulmonary arterial hypertension while removing the PH‑ILD indication from its label. The company says it will fund the settlement from ongoing YUTREPIA sales and its cash balance.
Why it matters
The settlement eliminates a major legal overhang, preserving YUTREPIA’s market presence and removing litigation risk for both companies (the company says it expects to fund the payments from sales and cash). No additional financing is required, which should support liquidity and allow continued investment in the pipeline.
Key facts
- 1Liquidia will pay a total of $380.7 million in installments during 2026‑2027. stocktitan.net
- 2The first payment is $175 million due within 30 business days. stocktwits.com
- 3Additional installments include two $72.7 million payments in early 2027 and $60.3 million for antitrust matters. stocktwits.com
- 4YUTREPIA net product sales were $222.7 million in Q3 2026 (preliminary, unaudited). stocktitan.net
- 5Liquidia held $396.1 million in cash and cash equivalents as of September 30 2026. stocktitan.net
- 6The settlement removes the PH‑ILD indication from YUTREPIA’s label and ends promotion for that use. stocktwits.com
Open questions
- Materials 26 and 32 report different total settlement amounts ($320.4 million and $330.4 million) that conflict with the $380.7 million figure in the majority of sources.
Summary written by AlphAI AI Desk from 20 of 59 sources. Not investment advice. Figures are as stated by the linked sources.